Metabolic Dysfunction is Associated with Steatosis but No Other Histologic Features in Nonalcoholic Fatty Liver Disease

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2022 Jun 6

PMID 35665109

Authors

Yi-Ning Dai

Cheng-Fu Xu

Hong-Ying Pan

Hai-Jun Huang

Mei-Juan Chen

You-Ming Li

Chao-Hui Yu

Affiliations

Soon will be listed here.

Abstract

Background: Recently, nonalcoholic fatty liver disease (NAFLD) has been renamed metabolic-associated fatty liver disease (MAFLD). Based on the definition for MAFLD, a group of non-obese and metabolically healthy individuals with fatty liver are excluded from the newly proposed nomenclature.

Aim: To analyze the histologic features in the MAFLD and non-MAFLD subgroups of NAFLD.

Methods: Eighty-three patients with biopsy-proven NAFLD were separated into MAFLD and non-MAFLD groups. The diagnosis of MAFLD was established as hepatic steatosis along with obesity/diabetes or evidence of metabolic dysfunction. The histologic features were compared according to different metabolic disorders and liver enzyme levels.

Results: MAFLD individuals had a higher NAFLD activity score ( = 0.002) and higher severity of hepatic steatosis (42.6% Grade 1, 42.6% Grade 2, and 14.8% Grade 3 in MAFLD; 81.8% Grade 1, 13.6% Grade 2, and 4.5% Grade 3 in non-MAFLD; = 0.007) than the non-MAFLD group. Lobular and portal inflammation, hepatic ballooning, fibrosis grade, and the presence of nonalcoholic steatohepatitis (NASH) and significant fibrosis were comparable between the two groups. The higher the liver enzyme levels, the more severe the grades of hepatic steatosis (75.0% Grade 1 and 25.0% Grade 2 in normal liver function; 56.6% Grade 1, 39.6% Grade 2, and 3.8% Grade 3 in increased liver enzyme levels; 27.8% Grade 1, 27.8% Grade 2, and 44.4% Grade 3 in liver injury; < 0.001). Patients with liver injury (alanine aminotransferase > 3 × upper limit of normal) presented a higher severity of hepatocellular ballooning ( = 0.021). Moreover, the grade of steatosis correlated significantly with hepatocellular ballooning degree ( = 0.338, = 0.002) and the presence of NASH ( = 0.466, < 0.001).

Conclusion: Metabolic dysfunction is associated with hepatic steatosis but no other histologic features in NAFLD. Further research is needed to assess the dynamic histologic characteristics in NAFLD based on the presence or absence of metabolic disorders.

References

Kleiner D, Brunt E, Wilson L, Behling C, Guy C, Contos M . Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019; 2(10):e1912565. PMC: 6784786. DOI: 10.1001/jamanetworkopen.2019.12565. View

Siddiqui M, Harrison S, Abdelmalek M, Anstee Q, Bedossa P, Castera L . Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2017; 67(5):2001-2012. PMC: 5906171. DOI: 10.1002/hep.29607. View

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

Brunt E, Kleiner D, Wilson L, Belt P, Neuschwander-Tetri B . Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011; 53(3):810-20. PMC: 3079483. DOI: 10.1002/hep.24127. View

Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View

ZELMAN S . The liver in obesity. AMA Arch Intern Med. 1952; 90(2):141-56. DOI: 10.1001/archinte.1952.00240080007002. View

Tiniakos D . Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol. 2009; 22(6):643-50. DOI: 10.1097/MEG.0b013e32832ca0cb. View

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L . Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018; 24(30):3361-3373. PMC: 6092580. DOI: 10.3748/wjg.v24.i30.3361. View

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016; 59(6):1121-40. DOI: 10.1007/s00125-016-3902-y. View

10.

Younes R, Bugianesi E . NASH in Lean Individuals. Semin Liver Dis. 2019; 39(1):86-95. DOI: 10.1055/s-0038-1677517. View

11.

Di Sessa A, Guarino S, Umano G, Arenella M, Alfiero S, Quaranta G . MAFLD in Obese Children: A Challenging Definition. Children (Basel). 2021; 8(3). PMC: 8005020. DOI: 10.3390/children8030247. View

12.

Wong V, Chan W, Chitturi S, Chawla Y, Dan Y, Duseja A . Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2017; 33(1):70-85. DOI: 10.1111/jgh.13857. View

13.

Kim D, Kim W, Joo S, Han J, Kim J, Harrison S . Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. J Gastroenterol. 2019; 55(3):330-341. DOI: 10.1007/s00535-019-01628-z. View

14.

Dam-Larsen S, Becker U, Franzmann M, Larsen K, Christoffersen P, Bendtsen F . Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009; 44(10):1236-43. DOI: 10.1080/00365520903171284. View

15.

Li H, Guo M, An Z, Meng J, Jiang J, Song J . Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. Int J Environ Res Public Health. 2020; 17(6). PMC: 7143027. DOI: 10.3390/ijerph17061818. View

16.

Woo J, Ho S, Yu A, Sham A . Is waist circumference a useful measure in predicting health outcomes in the elderly?. Int J Obes Relat Metab Disord. 2002; 26(10):1349-55. DOI: 10.1038/sj.ijo.0802080. View

17.

Eshraghian A, Nikeghbalian S, Geramizadeh B, Kazemi K, Shamsaeefar A, Malek-Hosseini S . Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. Clin Res Hepatol Gastroenterol. 2019; 44(4):572-578. DOI: 10.1016/j.clinre.2019.09.002. View

18.

Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D . What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int. 2020; 40(6):1254-1261. DOI: 10.1111/liv.14478. View

19.

Stefan N, Schick F, Haring H . Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017; 26(2):292-300. DOI: 10.1016/j.cmet.2017.07.008. View

20.

Huang H, Sun Z, Pan H, Chen M, Tong Y, Zhang J . Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep. 2016; 6:30853. PMC: 4976343. DOI: 10.1038/srep30853. View